Candidemia in the Intensive Care Unit

“…is among the major causes of severe systemic infections. Previously nonpathogenic species (e.g., C. glabrata , C. krusei , C. tropicalis , and C. parapsilosis ) have emerged as nosocomial threats, and the progress in the emergence of resistance to existing drugs has also been high . Co‐infections in HIV immunocompromised patients bring a new therapeutic challenge .…”

Section: Introductionmentioning

confidence: 99%

Synthesis, activity, and docking studies of eugenol‐based glucosides as new agents against Candida sp.

et al. 2018

View full text Add to dashboard Cite

Seventeen new synthetic derivatives of eugenol (6, 8-15 and 8'-15') were planned following literature reports on antifungal activities of nitroeugenol and eugenol glucoside. The anti-Candida activity of these compounds was investigated by in vitro assay, and the cytotoxicity evaluation was performed with the most active compounds. The peracetylated glucosides presented better biological results than their hydroxylated analogues. The glucoside 11, a 4-nitrobenzamide, showed the best potency (MIC range 11.0-151.84 μm), the wider spectrum of action, and overall the best selectivity indexes, especially against C. tropicalis (~30) and C. krusei (~15). To investigate its possible mechanism of action, glucoside 11 was subjected to molecular docking studies with Candida sp. enzymes involved in ergosterol biosynthesis. Results have shown that the peracetyl glucosyl moiety and the 4-nitrobenzamide group in 11 are effectively involved in its high affinity with the active site of squalene epoxidase.

show abstract

“…The incidence of IC is increasing and is particularly common in critical care environments. The epidemiology will differ depending on the patient cohort treated, trends of antifungal use, and geographically . With the increased use of fluconazole, the incidence of inherently fluconazole resistant spp.…”

Section: Infections Caused By Candida Sppmentioning

confidence: 99%

“…The epidemiology will differ depending on the patient cohort treated, trends of antifungal use, and geographically. 35 With the increased use of fluconazole, the incidence of inherently fluconazole resistant spp. such as C. glabrata and C. krusei increases.…”

Section: Infec Ti On S C Aus Ed By C Andida S Ppmentioning

confidence: 99%

Can intravenous antifungal therapy be safely used in the outpatient parenteral antimicrobial therapy (OPAT) setting?

Rae

Kenny

Muldoon

2019

Mycoses

View full text Add to dashboard Cite

Summary Outpatient parenteral antimicrobial therapy (OPAT) is an established treatment option for patients with a variety of infections who require a period of intravenous therapy, are clinically stable, and do not require continuous monitoring. Many patients with fungal infections require prolonged therapy due to resistance or intolerance to oral antifungal agents. Despite the widespread use of OPAT by infection specialists, antifungal agents appear infrequently used in this setting. We suggest that with appropriate patient selection, patients with fungal infections could successfully be treated on OPAT.

show abstract

Candidemia in the Intensive Care Unit

Cited by 45 publications

References 121 publications

Post-sepsis immunosuppression depends on NKT cell regulation of mTOR/IFN-γ in NK cells

Post-sepsis immunosuppression depends on NKT cell regulation of mTOR/IFN-γ in NK cells

Synthesis, activity, and docking studies of eugenol‐based glucosides as new agents against Candida sp.

Can intravenous antifungal therapy be safely used in the outpatient parenteral antimicrobial therapy (OPAT) setting?

Contact Info

Product

Resources

About